MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II ( MK2 ). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease. In Vitro Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner.. MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone. MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100. MMI-0100 does not induce EC apoptosis at any dose. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: human endothelial cell (EC) and smooth muscle cell (SMC) Concentration: 0.25, 0.5, and 1 mM Incubation Time: 24 hours Result: Slightly increased cell proliferation in both cell types compared to control cells. In Vivo MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 12-week-old C57Bl/6 wild type mice (intimal hyperplasia) Dosage: 100 μM Administration: vein graft, 28 days Result: Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts. Form:Solid